These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35160296)

  • 1. Evaluation of Risk Prediction Models to Identify Cancer Therapeutics Related Cardiac Dysfunction in Women with HER2+ Breast Cancer.
    Suntheralingam S; Fan CS; Calvillo-Argüelles O; Abdel-Qadir H; Amir E; Thavendiranathan P
    J Clin Med; 2022 Feb; 11(3):. PubMed ID: 35160296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer.
    Di Lisi D; Madaudo C; Faro DC; Rossetto L; Triolo OF; Losi V; Galassi AR; Monte IP; Novo G
    J Cardiovasc Med (Hagerstown); 2024 Mar; 25(3):218-224. PubMed ID: 38305134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Features of trastuzumab-related cardiac dysfunction: deformation analysis outside left ventricular global longitudinal strain.
    Nhat GM; Hai NH; Duc VT; Tri HHQ; Hoa CN
    Front Cardiovasc Med; 2024; 11():1291180. PubMed ID: 38312233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nomogram for Predicting Risk of Cancer Therapy-Related Cardiac Dysfunction in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    Yu AF; Lin IH; Jorgensen J; Copeland-Halperin R; Feldman S; Ibtida I; Assefa A; Johnson MN; Dang CT; Liu JE; Steingart RM
    J Am Heart Assoc; 2023 Oct; 12(19):e029465. PubMed ID: 37750581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
    Houbois CP; Nolan M; Somerset E; Shalmon T; Esmaeilzadeh M; Lamacie MM; Amir E; Brezden-Masley C; Koch CA; Thevakumaran Y; Yan AT; Marwick TH; Wintersperger BJ; Thavendiranathan P
    JACC Cardiovasc Imaging; 2021 May; 14(5):962-974. PubMed ID: 33248962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis.
    Oikonomou EK; Kokkinidis DG; Kampaktsis PN; Amir EA; Marwick TH; Gupta D; Thavendiranathan P
    JAMA Cardiol; 2019 Oct; 4(10):1007-1018. PubMed ID: 31433450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
    Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
    J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of Integrating Heart Failure Risk Factors Into Impairment of Global Longitudinal Strain to Predict Anthracycline-Related Cardiac Dysfunction.
    Milks MW; Velez MR; Mehta N; Ishola A; Van Houten T; Yildiz VO; Reinbolt R; Lustberg M; Smith SA; Orsinelli DA
    Am J Cardiol; 2018 Apr; 121(7):867-873. PubMed ID: 29454478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The additional value of myocardial T1ρ mapping to T1 and T2 mapping for predicting subsequent cancer therapy-related cardiac dysfunction in breast cancer patients who received anthracyclines with/without trastuzumab.
    Li X; Shen H; Peng Y; Miao Z; Tu C; Zhang X; Wu Z; Zeng X; Zhang J
    Eur J Radiol; 2024 Dec; 181():111755. PubMed ID: 39342884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Therapeutics-Related Cardiac Dysfunction among Patients with Active Breast Cancer: A Cardio-Oncology Registry.
    Laufer-Perl M; Mor L; Milwidsky A; Derakhshesh M; Amrami N; Moshkovits Y; Arnold J; Topilsky Y; Arbel Y; Rozenbaum Z
    Isr Med Assoc J; 2020 Sep; 22(9):564-568. PubMed ID: 33236555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab.
    Thompson EW; Demissei BG; Smith AM; Brahmbhatt P; Wang J; Clark A; DeMichele A; Narayan V; Shah P; Sun L; Lefebvre B; Fradley MG; Carver JR; Tang WHW; Ky B
    JACC Basic Transl Sci; 2022 Jan; 7(1):1-10. PubMed ID: 35128203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction.
    Narayan HK; French B; Khan AM; Plappert T; Hyman D; Bajulaiye A; Domchek S; DeMichele A; Clark A; Matro J; Bradbury A; Fox K; Carver JR; Ky B
    JACC Cardiovasc Imaging; 2016 Oct; 9(10):1131-1141. PubMed ID: 27085442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy?: Impact of Temporal and Observer Variability.
    Altaha MA; Nolan M; Marwick TH; Somerset E; Houbois C; Amir E; Yip P; Connelly KA; Michalowska M; Sussman MS; Wintersperger BJ; Thavendiranathan P
    JACC Cardiovasc Imaging; 2020 Apr; 13(4):951-962. PubMed ID: 31864977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction.
    Beer LA; Kossenkov AV; Liu Q; Luning Prak E; Domchek S; Speicher DW; Ky B
    Circ Res; 2016 Oct; 119(10):1135-1144. PubMed ID: 27582370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Profile and Prognosis of a Real-World Cohort of Patients With Moderate or Severe Cancer Therapy-Induced Cardiac Dysfunction.
    Esteban-Fernández A; Carvajal Estupiñan JF; Gavira-Gómez JJ; Pernas S; Moliner P; Garay A; Sánchez-González Á; Fernández-Rozas I; González-Costello J
    Front Cardiovasc Med; 2021; 8():721080. PubMed ID: 34778393
    [No Abstract]   [Full Text] [Related]  

  • 16. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score.
    Rivero-Santana B; Saldaña-García J; Caro-Codón J; Zamora P; Moliner P; Martínez Monzonis A; Zatarain E; Álvarez-Ortega C; Gómez-Prieto P; Pernas S; Rodriguez I; Buño Soto A; Cadenas R; Palacios Ozores P; Pérez Ramírez S; Merino Salvador M; Valbuena S; Fernández Gasso L; Juárez V; Severo A; Terol B; de Soto Álvarez T; Rodríguez O; Brion M; González-Costello J; Canales Albendea M; González-Juanatey JR; Moreno R; López-Sendón J; López-Fernández T
    Eur Heart J; 2024 Aug; ():. PubMed ID: 39106857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monocyte-to-lymphocyte ratio as predictor of cancer therapy-related cardiotoxicity in patients with breast cancer: a pilot cohort study.
    Pivatto Júnior F; Santos ÂBS; Englert EF; Mazzutti G; Costa GOM; Saffi MAL; Liedke PER; Fritsch VH; Biolo A
    Breast Cancer Res Treat; 2023 Aug; 200(3):355-362. PubMed ID: 37273150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores.
    Glen C; Adam S; McDowell K; Waterston A; Tan YY; Petrie MC; Coats CJ; Lang NN
    JACC CardioOncol; 2023 Oct; 5(5):628-637. PubMed ID: 37969652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left atrial longitudinal strain as a predictor of Cancer therapeutics-related cardiac dysfunction in patients with breast Cancer.
    Park H; Kim KH; Kim HY; Cho JY; Yoon HJ; Hong YJ; Park HW; Kim JH; Ahn Y; Jeong MH; Cho JG
    Cardiovasc Ultrasound; 2020 Jul; 18(1):28. PubMed ID: 32693802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of and sex differences in cancer treatment-related cardiac dysfunction in trastuzumab-treated patients with salivary gland cancer: a retrospective cohort study.
    Tamura Y; Tamura Y; Tada Y
    Cardiooncology; 2024 Jul; 10(1):44. PubMed ID: 39020443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.